Search

Author/Creator Georgi, T.

1. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH‐HD2002 trial. Issue 3 (14th November 2018)

Authors:
Kurch, L.; Hasenclever, D.; Kluge, R.; Georgi, T.; Tchavdarova, L.; Golombeck, M.; Sabri, O.; Eggert, A.; Brenner, W.; Sykora, K.W.; Bengel, F.M.; Rossig, C.; Körholz, D.; Schäfers, M.; Feuchtinger, T.; Bartenstein, P.; Ammann, R.A.; Krause, T.; Urban, C.; Aigner, R.
Journal:
Pediatric blood & cancer
Issue:
Volume 66:Issue 3(2019)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL). (12th June 2019)

Authors:
Metzger, M.; Mauz‐Körholz, C.; Flerlage, J.; Bartelt, J.; Billett, A.; Choi, J.K.; Ehrhardt, M.; Georgi, T.; Hasenclever, D.; Wang, F.; Zhang, H.; Kaste, S.C.; Kluge, R.; Körholz, D.; Kurch, L.; Link, M.; Stoevesandt, D.; Hudson, M.M.; Krasin, M.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
55
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search